Bengaluru: Strides Pharma Science has announced that the U.S. Food and Drug Administration (USFDA) has concluded inspection with four observations at the Formulations Facility of Strides Pharma Inc. USA (SPI), a step-down wholly owned subsidiary of the Company, at Chestnut Ridge, New York, USA.
A routine current Good Manufacturing Practices (cGMP) inspection was conducted during the period December 17, 2025 to December 23, 2025.
At the conclusion of the inspection, the U.S. FDA has issued a Form 483 with four observations. These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products.
An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
Read also: Strides, Incepta partner to expand women health access with WHO prequalified contraceptive
“SPI will respond to these observations comprehensively to FDA within the stipulated time and is confident of addressing all the observations to the satisfaction of USFDA,” the company stated in a BSE filing.
Read also: Strides Pharma Science: Nandini Matiyani joins as Executive VP – Human Resources
Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor- funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries.
